---
title: "DEA clears Takeda narcolepsy pill Orzeyful; Pfizer halts Premarin sales in Canada"
id: "stat-news-4-stat-pharmalittle-we-re-reading-about-lilly-conflict-questions-a-dea-ok-for-a"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-lilly-conflict-questions-a-dea-ok-for-a"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/pharmalot/2026/11/13/lilly-conflict-questions-dea-okays-takeda-narcolepsy-pill/?utm_campaign=rss"
published_at: "2026-11-13T14:33:16.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# DEA clears Takeda narcolepsy pill Orzeyful; Pfizer halts Premarin sales in Canada
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-lilly-conflict-questions-a-dea-ok-for-a
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/pharmalot/2026/11/13/lilly-conflict-questions-dea-okays-takeda-narcolepsy-pill/?utm_campaign=rss)
- **Published At:** 2026-11-13T14:33:16.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The DEA has classified Takeda’s **Orzeyful** as a Schedule IV controlled substance, permitting U.S. launch after the agency removed a regulatory barrier. The company described the drug as the first therapy to target the underlying cause of narcolepsy. - Takeda set the U.S. list price at $16,500 per 60-tablet bottle across strengths. The source reported about 120,000 people in the U.S. have narcolepsy. - Pfizer will stop selling **Premarin** in Canada following an internal review; the product had been supplied as a vaginal cream and three oral tablet strengths. - Canadian supplies of Premarin vaginal cream have been in shortage since June, and the company will not provide further batches. - The source noted rising demand for hormone replacement therapy in the U.S., attributed to the U.S. Food and Drug Administration removing long-standing safety warnings roughly a year earlier; some other menopause HRT products in Canada are also facing supply constraints. - The article cited Reuters reporting for the Takeda and Pfizer items and identified the story as a STAT+ exclusive beyond the free items. - The source did not report clinical trial design details, efficacy or safety data, dosing regimens, or regulatory review timelines beyond the DEA scheduling action and the pricing and availability statements.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/pharmalot/2026/11/13/lilly-conflict-questions-dea-okays-takeda-narcolepsy-pill/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/pharmalot/2026/11/13/lilly-conflict-questions-dea-okays-takeda-narcolepsy-pill/?utm_campaign=rss) [Cancer](https://www.statnews.com/topic/cancer/) [research](https://www.statnews.com/topic/research/) [RFK Jr.](https://www.statnews.com/topic/rfk-jr/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Madness 2027](https://www.statnews.com/feature/stat-madness/apply/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)Newsletter[Pharmalot](https://www.statnews.com/category/pharma/pharmalot/) # Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more ## Pfizer will no longer sell its hormone replacement therapy Premarin in Canada * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/pharmalot/2026/11/13/lilly-conflict-questions-dea-okays-takeda-narcolepsy-pill/?utm_campaign=rss) ![an anthropomorphized red and blue pill illustrated in the style of the famous american gothic painting](https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg) Alex Hogan/STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Nov. 13, 2026 Pharmalot Columnist, Senior Writer ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") 2. [](https://x.com/Pharmalot "X") ed.silverman@statnews.com Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to tidy the Pharmalot grounds, catch up on our reading, promenade with the official mascots, and of course, hold a listening party with Mrs. Pharmalot. So far, the rotation will include [this](https://youtu.be/S7QL94bEpro?si=tj6_eii3O5Sp-tMJ), [this](https://youtu.be/PcO4rA1Pa2w?si=r1Wj-EoMQ0ejfLOP), [this](https://youtu.be/MljXBJv7mA8?si=5neVp1kfmNgCPmGW), [this](https://youtu.be/5YFYda1Bv0s?si=lLa6KOC3l54I8y08), and [this](https://youtu.be/3soeVVwpL9I?si=2C--jbJ6R-YaaPh1). And what about you? This may be an opportunity to tend to the grounds. You could take a long walk in a park or wander about city streets. Holidays are approaching so perhaps this an opportunity to go shopping and boost the economy. Or you could be zen for a while, relax your mind and do absolutely nothing. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.… **Takeda reported that its narcolepsy pill, the first treatment to target the underlying cause ​of the rare sleep disorder, is now available in the U.S. after ‌the U.S. Drug Enforcement Administration removed the final regulatory hurdle for its rollout,** [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/takeda-launches-sleep-disorder-pill-us-after-dea-clearance-removes-final-hurdle-2026-11-12/) notes. The DEA has classified Orzeyful as a Schedule IV controlled substance, a category considered to have a ​low potential for abuse and dependence. The U.S. list price has been ⁠set at $16,500 per 60-tablet bottle, across all strengths. About ⁠120,000 people in the U.S. have the disorder. Advertisement **Pfizer will no longer sell its hormone replacement therapy Premarin, which has been available as a vaginal cream and three strengths of oral ​tablets, in Canada following an internal review** , [Reuters](https://www.reuters.com/world/pfizer-stop-selling-premarin-hormone-therapy-canada-2026-11-12/) reports. Premarin vaginal cream, used to treat ‌symptoms of menopause, has been in shortage in Canada since June and no further batches will be supplied. Demand for hormone replacement therapy has been ​rising, particularly in the U.S., where prescriptions have increased after the U.S. Food and Drug Administration removed long-standing safety warnings a year ago. Some other hormone therapy ⁠products to treat menopause symptoms are also facing supply constraints in Canada. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [pharmalittle](https://www.statnews.com/topic/pharmalittle/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Pharmalot Columnist, Senior Writer 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_1544077528-80x80.jpeg) [American Cancer Society revises guidelines, urges routine PSA screening for prostate cancer](https://www.statnews.com/2026/11/12/prostate-cancer-screening-guidelines-updated-acs/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/11/GettyImages-2304299477-80x80.jpg) [Senator-elect Abdul El-Sayed on restoring trust in science, the state of public health, and RFK Jr.](https://www.statnews.com/2026/11/13/senator-abdul-el-sayed-interview-public-health-rfk-jr-trust-in-science/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/05/AP26023803702193-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say](https://www.statnews.com/2026/11/13/oura-acquisition-counsel-health-eli-lilly/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/DisConnect_021-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Across the U.S., homegrown experiments aim to save kids from their phones](https://www.statnews.com/2026/11/13/phone-addiction-young-people-fight-back-attention-activism/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/11/GettyImages-2250612428-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Senators introduce bill to curb conflicts of interest on preventive care panel](https://www.statnews.com/2026/11/13/uspstf-preventive-care-panel-senators-target-conflicts-of-interest/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_6400491-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA warns GLP-1 drugs carry potential risk of rare eye condition](https://www.statnews.com/2026/11/09/glp-1-drugs-potential-risk-rare-eye-condition-naion-fda/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_391451620_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/) 3. ![](https://www.statnews.com/wp-content/uploads/2019/09/AP_060324030695-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves novel Bayer drug to reduce recurrence of stroke](https://www.statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_1874804219-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Beyond statins, one drug lowered heart attack risk by 20%](https://www.statnews.com/2026/11/05/repatha-vs-zetia-cholesterol-study-heart-attack-risk/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/11/F0367611-Adeno-associated_virus_illustration-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [New tumor cases show common gene therapy tool can come with risk](https://www.statnews.com/2026/11/06/novartis-zolgensma-gene-therapy-tumor-risk/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 12, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more ](https://www.statnews.com/pharmalot/2026/11/12/fda-fast-track-review-shelved-canadian-importer-arrested/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 11, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more ](https://www.statnews.com/pharmalot/2026/11/11/dems-eye-trump-mfn-deals-fewer-drug-launches-in-europe/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 10, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [
## Related Clinical Research

- [Blackstone invests in Pfizer’s monthly obesity therapy program](https://medichelpline.com/clinical-feed/stat-news-0-stat-blackstone-backs-pfizer-s-bet-on-monthly-obesity-treatment.md)
- [FDA Shelves Makary’s Fast-Track Voucher Program; Senate Readies Vote on Overton](https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-fda-shelving-fast-track-review-a-canadian.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Later bedtimes and late eating tied to higher metabolic syndrome risk](https://medichelpline.com/clinical-feed/medical-news-today-0-eating-and-sleeping-later-associated-with-increased-health-risks.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.